To investigate the effect of tacrolimus combined with mycophenolate mofetil on primary nephrotic syndrome (PNS) and its influence on renal function and recurrence of patients.

A total of 100 PNS patients in Zhumadian Central Hospital from February 2015 to February 2020 were enrolled, and they were divided into combination group and control group by random number table methods, with 50 cases in each group. The patients in the control group took tacrolimus capsule, the combined group took mycophenolate capsule on the basis of the control group, after 3 months of treatment, the clinical efficacy, renal function indicators such as serum creatinine (SCr), cystatin C (Cys-C), blood urea nitrogen (BUN), 24 hours urinary protein quantification (24hUPQ) and adverse reaction rate were compared between groups. The recurrence rate was compared within one year.

The total efficacy rate of combined group was significantly higher than that of control group (86.00% vs 62.00%, P<0.05); levels of BUN, Cys-C, SCr, and 24hUPQ had no significant difference between groups before treatment (P>0.05); after treatment, the levels of BUN、Cys-C, SCr, 24hUPQ in the two groups were significantly lower than those before treatment (P<0.05), and the levels of BUN, Cys-C, SCr, 24hUPQ in the combined group were significantly lower than those in the control group (P<0.05); the recurrence rate in combined group was significantly lower than that in control group (8.00%vs. 22.00%, P<0.05); there was no significant difference in the incidence rate of adverse reactions between two groups (8.00%vs. 4.00%, P>0.05).

Application of tacrolimus combined with mycophenolate mofetil is an effective and safe way to ameliorate renal function and reduce recurrence rate for PNS patients, which is worthy of clinical promotion.

Primary nephrotic syndrome; Tacrolimus; Renal function